How Does BPC-157 Work? Mechanism of Action Explained

BPC-157 does not currently have a single clinically established mechanism of action. Instead, researchers have identified several experimental pathways that may help explain observations reported in laboratory and animal models.

These include fibroblast migration, FAK-paxillin signalling, angiogenesis, VEGFR2 activation and nitric-oxide regulation.

If you are new to the compound, our introductory guide explains what BPC-157 is before exploring these mechanisms in greater detail.

BPC-157 and fibroblasts

Fibroblasts are cells involved in producing and organising extracellular-matrix components, including collagen.

Experimental tendon research has reported changes in fibroblast migration, spreading and cellular signalling following exposure to BPC-157.

This pathway is particularly relevant to studies involving tendons and connective tissue. For more detail, see our article covering BPC-157 and tendon research.

FAK and paxillin signalling

FAK and paxillin are proteins involved in cellular attachment, migration and cytoskeletal organisation.

Experimental BPC-157 research has reported changes in the phosphorylation of these signalling proteins, providing one possible explanation for the increased cell migration observed in some laboratory models.

This may also help explain why BPC-157 is frequently discussed in relation to ligament, muscle and connective-tissue research.

BPC-157 and angiogenesis

Angiogenesis is the biological process through which new blood vessels develop from existing vessels.

Experimental work has associated BPC-157 with signalling through vascular endothelial growth factor receptor 2, commonly abbreviated to VEGFR2.

Researchers have examined a proposed pathway involving:

BPC-157 → VEGFR2 → Akt → eNOS → vascular signalling

This is particularly relevant to experimental tissue-repair models because vascular supply plays an important role in tissue maintenance and remodelling.

BPC-157 and nitric oxide

Nitric oxide is a signalling molecule involved in vascular tone and numerous other physiological processes.

Several BPC-157 experiments have investigated interactions between the peptide and nitric-oxide pathways. This research has included compounds that inhibit or alter nitric-oxide synthesis.

The nitric-oxide pathway also appears frequently in BPC-157 gastrointestinal research.

Does this explain how BPC-157 works in humans?

Not conclusively.

These mechanisms provide research hypotheses based largely on laboratory and animal experiments. They do not establish a proven therapeutic mechanism in humans.

For a broader review of the evidence, see our guide to BPC-157 studies and research and our separate examination of BPC-157 clinical trials and human research.

Researchers can view compound specifications on the Kensington Labs BPC-157 research peptide page.

Research use only. Not intended for human consumption.